Piper Sandler initiated coverage of Camp4 Therapeutics (CAMP) with an Overweight rating and $18 price target The company is is pioneering development of regulatory RNAs as a novel therapeutic modality, the analyst tells investors in a research note. The firm estimates Camp4 holds pro forma cash of $79M to fund operations into Q2 of 2026.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAMP: